Tempus AI, Inc. was established in 2015 by Eric Lefkofsky in Chicago, inspired by his wife's cancer diagnosis. From its beginnings as Tempus Labs, the company set out to apply artificial intelligence to clinical and molecular data to improve patient care. It went public on Nasdaq in June 2024 under the ticker “TEM,” raising approximately $410 million and debuting at a $6+ billion valuation .
Tempus builds and maintains one of the most extensive multimodal data libraries in healthcare—over 40 million records with genomic, imaging, transcriptomic, and clinical text data—supporting oncologists, cardiologists, neurologists, and psychiatrists. Its flagship Tempus One platform combines genomics sequencing services like xT, xF (liquid biopsy), xE (exome), and now xH—its first whole genome sequencing test tailored for hematologic cancers. These offerings are complemented by clinical AI tools such as generative AI-enabled trial matching (TIME), data querying assistants, and patient-facing app “olivia” for consolidated medical record access.
Tempus has forged strategic collaborations and acquisitions to scale its ecosystem. Key partnerships include AstraZeneca and Pathos AI to build multimodal foundation models for oncology (backed by $200 million), plus Pfizer, GSK, and Illumina collaborations . In early 2025, it acquired Deep 6 AI—integrated with over 30 million patient records across 750 sites—for optimizing clinical trial recruitment. It also absorbed Ambry Genetics in February 2025 to broaden into hereditary disease diagnostics beyond oncology.
Tempus continues to innovate and grow along multiple fronts. Its Fuses program, launched mid 2025, applies its massive data library to create a diagnostic AI platform offering an expanded catalog of algorithmic tests. The olivia app, boasting connections to over 1,000 health systems and personal health data integration, helped drive a 39% stock jump upon release. Internationally, a joint venture with SoftBank expands its AI-driven clinical services into Japan. With its foundation in big data, AI platforms, and deep clinical ties, Tempus is carving out a significant role at the convergence of precision diagnostics, therapeutic R&D, and patient-driven healthcare.